Recombinant biologic products versus nutraceuticals from plants – a regulatory choice?

33Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Biotechnology has transformed the potential for plants to be a manufacturing source of pharmaceutical compounds. Now, with transgenic and transient expression techniques, virtually any biologic, including vaccines and therapeutics, could be manufactured in plants. However, uncertainty over the regulatory path for such new pharmaceuticals has been a deterrent. Consideration has been given to using alternative regulatory paths, including those for nutraceuticals or cosmetic agents. This review will consider these possibilities, and discuss the difficulties in establishing regulatory guidelines for new pharmaceutical manufacturing technologies.

Cite

CITATION STYLE

APA

Drake, P. M. W., Szeto, T. H., Paul, M. J., Teh, A. Y. H., & Ma, J. K. C. (2017). Recombinant biologic products versus nutraceuticals from plants – a regulatory choice? British Journal of Clinical Pharmacology. Blackwell Publishing Ltd. https://doi.org/10.1111/bcp.13041

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free